Eliem press releases
WebNov 14, 2024 · This press release contains forward-looking statements, including, without limitation, statements relating to: the advancement of Eliem’s pipeline; the continued development and clinical and therapeutic potential of ETX-155 and Eliem’s Kv7 channel opener program; the commencement of the referenced Phase 2a trial of ETX-155 in … WebMar 6, 2024 · SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company …
Eliem press releases
Did you know?
WebSep 13, 2024 · This press release contains forward-looking statements, including, without limitation, statements relating to: Eliem’s plans to initiate clinical trials of ETX-155 and the timing thereof; anticipated data readouts of ETX-810 and ETX-155 and the timing thereof; the progression of the Kv7.2/3 and next-generation anxiolytic preclinical programs ... Web1 day ago · On April 13, 2024, the Company issued a press release announcing the appointment of Mr. Azelby. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7. ...
WebSEATTLE and CAMBRIDGE, United Kingdom, Feb. 09, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. ( Nasdaq: ELYM) (“Eliem” or the “Company”), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the … Web1 day ago · The MarketWatch News Department was not involved in the creation of this content. SEATTLE, April 13, Apr 13, 2024 (GLOBE NEWSWIRE via COMTEX) -- SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook ...
WebAug 13, 2024 · Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares. SEATTLE … WebOct 5, 2024 · Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2024 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing ...
WebFeb 9, 2024 · Eliem Therapeutics, Inc., a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, …
WebEliem Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, … city lights maintenanceWebJul 18, 2024 · Eliem expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Eliem's ... city lights milwaukeeWebMar 20, 2024 · Get the latest news and real-time alerts from Eliem Therapeutics, Inc. (ELYM) stock at Seeking Alpha. Eliem Therapeutics, Inc. (ELYM) Latest Stock News … city lights kklWebOct 5, 2024 · SEATTLE and CAMBRIDGE, United Kingdom, Oct. 05, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. ( Nasdaq: ELYM ), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the … city lights miw lyricsWebGet the latest Eliem Therapeutics, Inc. (ELYM) stock news and headlines to help you in your trading and investing decisions. city lights lincolnWebMar 25, 2024 · SEATTLE and CAMBRIDGE, England, March 25, 2024 /PRNewswire/ -- Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today ... city lights liza minnelliWebAug 10, 2024 · SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company … city lights ministry abilene tx